DXR - NASDAQ

Daxor Corporation

DXR·NASDAQ

$11.09

+3.3%

HealthcareMedical - Instruments & Supplies

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$55.86M

EPS1.8400

P/E Ratio6.03

Earnings Date08/20/2026

46.01M

Assets

26%

3Y+52.0%

5Y+178.0%

10Y+123.0%

122.59K

Total Liabilities

-85%

3Y-91.0%

5Y-86.0%

10Y-98.0%

45.89M

Total Equity

28%

3Y+58.0%

5Y+193.0%

10Y+199.0%

Daxor Corporation Funding & Solvency Profile

DXR · NASDAQ

Current Assets

Cash & Cash Equivalents0.00

Net Receivables0.00

Inventory0.00

Other Current Assets0.00

Total Current Assets0

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments46.00M

Other Non-Current Assets9.86K

Total Non-Current Assets46 M

Total Assets

46.01M

Financial Health Analysis

Debt-to-Equity Ratio

0.00x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

0% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Daxor Corporation Balance Sheet

DXR • NASDAQ

Daxor Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	0.0	0.0	0.0	0.0	710.7K	617.8K	0.0	0.0	1.1M	2.2M	2.5M	0.0	0.0	0.0	59.6K	57.7K	277.1K	2.5M	2M	2.8M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.8M	53.9M	53.3M	68.3M	74.9M	67M
Cash & Short-Term Investments	0.0	0.0	0.0	0.0	710.7K	617.8K	0.0	0.0	1.1M	2.2M	2.5M	0.0	0.0	0.0	59.6K	57.7K	277.1K	2.5M	2M	2.8M
Net Receivables	0.0	9.7K	14.2K	17.2K	30.7K	29.3K	32.7K	33.7K	45.3K	45.9K	33.4K	324.8K	144.7K	148.1K	23.3M	32.6M	16.9M	2.8M	10.5M	174.1K
Accounts Receivables	0.0	9.7K	14.2K	17.2K	30.7K	29.3K	0.0	33.7K	0.0	0.0	0.0	0.0	144.7K	148.1K	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	32.7K	0.0	45.3K	45.9K	33.4K	324.8K	0.0	0.0	23.3M	32.6M	6.3M	205.6K	214.3K	174.1K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	301.5K	363.6K	454.4K	426.8K	255.8K	171K
Prepaids	0.0	0.0	11.7K	20.6K	23.1K	0.0	0.0	0.0	37.8K	33.2K	28.2K	24.5K	26.6K	0.0	209.3K	130.6K	104.4K	131.9K	145.8K	115.1K
Other Current Assets	0.0	8.9K	0.0	0.0	0.0	-647.1K	0.0	357K	1.1M	2.6M	2.5M	215.3K	1.2M	2.2M	23.3M	32.5M	10.9M	337.5K	12.8M	7.2M
Total Current Assets	0.0	18.6K	25.9K	37.8K	764.5K	0.0	32.7K	36.7K	45.3K	2.6M	2.5M	324.8K	278.6K	148.1K	81.7M	87M	71M	74.5M	100.5M	77.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4M	4.2M	4.2M	2.3M	2.1M	763.8K
Long-Term Investments	46M	36.6M	34.8M	30.2M	24.2M	15.7M	14M	17.2M	18.1M	18M	18.4M	44.5M	46M	54M	55.8M	53.9M	63.8M	68.3M	74.9M	67M
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6M	9M	10.6M	8.1M	15.7M	15.3M
Other Non-Current Assets	9.9K	0.0	0.0	0.0	0.0	0.0	0.0	-17.2M	-18.1M	-18M	-18.4M	-44.5M	-46M	-54M	-60.3M	-62.8M	-74.4M	-76.4M	-90.6M	-82.2M
Total Non-Current Assets	46M	36.6M	34.8M	30.2M	24.2M	15.7M	14M	17.2M	18.1M	18M	18.4M	44.5M	46M	54M	4M	4.2M	4.2M	2.3M	2.1M	796K
Other Assets	0.0	36.6M	34.9M	30.3M	25M	16.6M	198.5K	354K	1.1M	33.2K	28.2K	1.2M	1.1M	2.2M	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	46M	36.6M	34.9M	30.3M	25M	16.6M	14.2M	17.6M	19.3M	20.6M	20.9M	46M	47.4M	56.3M	85.7M	91.2M	75.2M	76.8M	102.6M	78.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	110.3K	103.1K	62.4K	87.4K	80K	78.8K	72.5K	75K	7.8K	9.1K	15.9K	27.8K	49.9K	612.3K	3.4M	1.5M	3.2M	498.2K	413K
Accounts Payable	0.0	110.3K	103.1K	62.4K	87.4K	80K	78.8K	72.5K	75K	7.8K	9.1K	15.9K	27.8K	11.3K	525.2K	436.5K	533.6K	604.4K	498.2K	413K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.6K	87.1K	3M	943.1K	2.6M	0.0	0.0
Short Term Debt	0.0	0.0	0.0	0.0	715.8K	627K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.3K	34K	34K	32.5K	35.5K	0.0	87.1K	3M	943.1K	2.6M	1.3M	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1M	-2.2M	-2.4M	0.0	0.0	0.0	38.7K	51.9K	46.9K	33.3K	7.4K	2.8K
Other Current Liabilities	0.0	0.0	0.0	0.0	3.2K	0.0	0.0	-72.5K	-75K	-7.8K	-9.1K	-15.9K	-27.8K	-49.9K	-650.9K	-3.5M	-1.5M	-3.3M	-505.6K	-415.7K
Total Current Liabilities	0.0	110.3K	103.1K	62.4K	806.4K	707K	78.8K	72.5K	75K	7.8K	9.1K	15.9K	27.8K	11.3K	49.3M	43.9M	27.2M	33M	47.2M	32.5M
NON-CURRENT LIABILITIES
Long Term Debt	112K	730K	755.7K	1.2M	3M	170.7K	1.3M	4.5M	4.3M	2.8M	3.8M	21.4M	20.2M	10.7M	14.1M	27.4M	11.2M	13.5M	3.8M	0.0
Other Non-Current Liabilities	10.6K	0.0	0.0	0.0	0.0	0.0	0.0	-4.5M	-4.3M	-2.8M	-3.8M	-21.4M	-20.2M	0.0	-14.1M	-27.4M	-11.2M	-13.5M	-3.8M	0.0
Total Non-Current Liabilities	122.6K	730K	755.7K	1.2M	3M	170.7K	1.3M	4.5M	4.3M	2.8M	3.8M	21.4M	20.2M	10.7M	244K	300.1K	346.9K	390.3K	430.6K	3.5M
Other Liabilities	0.0	840.3K	858.8K	1.3M	3.8M	877.7K	14.1K	37.4K	1.1M	2.5M	2.6M	93.3K	750.6K	10.5M	0.0	0.0	0.0	0.0	0.0	-3.5M
Total Liabilities	122.6K	840.3K	858.8K	1.3M	3.8M	877.7K	1.4M	4.6M	5.6M	5.3M	6.5M	21.5M	21M	21.2M	49.5M	44.2M	27.6M	33.4M	47.6M	32.5M
SHAREHOLDERS' EQUITY
Treasury Stock	-4.5M	-4.5M	-4.8M	-8.8M	-10.6M	-10.6M	-14.9M	-14.9M	-15M	-14.7M	-14.3M	-13.4M	-12.7M	-12.4M	-11.8M	-11.6M	-11.4M	-10.9M	-8.4M	-6M
Common Stock	55.3K	54.1K	53.2K	53.2K	53.2K	53.2K	53.2K	53.2K	53.2K	53.2K	10.8M	10.7M	10.7M	53.2K	53.2K	53.2K	53.2K	53.2K	53.2K	53.2K
Additional Paid-In Capital	15.5M	14.6M	13.7M	12.9M	12.1M	11.4M	11M	10.8M	10.7M	10.7M	10.8M	0.0	0.0	10.7M	10.7M	10.7M	10.7M	10.7M	10.6M	10.4M
Retained Earnings	0.0	25.6M	25.1M	24.8M	19.6M	14.9M	16.6M	17.1M	8.5M	10.4M	10.2M	10.6M	13M	21M	24.7M	33M	32.2M	32.2M	23.5M	12.8M
Accumulated Other Comprehensive Income/Loss	34.8M	0.0	0.0	24.8M	19.6M	14.9M	16.6M	17.1M	0.0	0.0	0.0	0.0	0.0	0.0	12.6M	14.9M	16M	11.5M	29.2M	28.4M
Other Total Stockholders' Equity	0.0	0.0	0.0	-24.8M	-19.6M	-14.9M	0.0	-17.1M	0.0	0.0	-10.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	45.9M	35.8M	34M	29M	21.2M	15.7M	12.8M	13.1M	13.8M	15.3M	14.4M	24.6M	26.4M	35.1M	36.2M	47M	47.6M	43.5M	54.9M	45.6M
Total Equity	45.9M	35.8M	34M	29M	21.2M	15.7M	12.8M	13.1M	13.8M	15.3M	14.4M	24.6M	26.4M	35.1M	36.2M	47M	47.6M	43.5M	54.9M	45.6M
SUMMARY
Total Liabilities & Equity	46M	36.6M	34.9M	30.3M	25M	16.6M	14.2M	17.6M	19.3M	20.6M	20.9M	46M	47.4M	56.3M	85.7M	91.2M	75.2M	76.8M	102.6M	78.2M
Total Investments	46M	36.6M	34.8M	30.2M	24.2M	15.7M	14M	17.2M	18.1M	18M	18.4M	44.5M	46M	54M	111.6M	107.8M	117.1M	136.7M	149.8M	133.9M
Total Debt	112K	730K	755.7K	1.2M	3M	170.7K	1.3M	4.5M	4.3M	2.8M	3.8M	21.4M	20.2M	0.0	14.1M	27.4M	11.2M	13.5M	3.8M	3.5M
Net Debt	112K	730K	755.7K	1.2M	2.3M	-447.1K	1.3M	4.5M	3.2M	617.9K	1.4M	21.4M	20.2M	0.0	14M	27.3M	10.9M	10.9M	1.8M	644.2K
Shares Outstanding	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452	4,984,452

SEC Filings

DXR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 26, 2026	January 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 23, 2026	January 23, 2026	2026	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 07, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 01, 2025	June 24, 2025	2025	View Filing
DEF 14A DEF 14A 2025 N/A	June 06, 2025	June 06, 2025	2025	View Filing
8-K 8-K 2024 N/A	July 18, 2024	July 15, 2024	2024	View Filing
DEF 14A DEF 14A 2024 N/A	June 21, 2024	June 21, 2024	2024	View Filing
8-K 8-K 2024 N/A	June 05, 2024	May 30, 2024	2024	View Filing
8-K 8-K 2024 N/A	March 25, 2024	March 25, 2024	2024	View Filing

Showing 1 to 10 of 154 filings

Related Guides

Blog Categories

Continue your DXR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.